Healthcare ❯ Pharmaceuticals

Oncology

Drug Development Cancer Treatments Immunology Cancer Treatment Drug Sales Immunotherapy Clinical Trials Pediatric Oncology Cancer Drugs Bladder Cancer Product Revenue Prostate Cancer Drugs Targeted Therapy Hematologic Malignancies Aesthetics RAS Pathway Inhibitors Product Sales Trodelvy Cancer Therapies Johnson & Johnson Precision Medicine Oncology Supportive Care Antibody Drug Conjugates Radiopharmaceuticals Breast Cancer Targeted Therapies

Johnson & Johnson Beats Q2 Estimates and Lifts Full‑Year Outlook

Strong drug sales powered the quarter with MedTech shortfalls and biosimilar losses keeping longer‑term risks in view.

Erasca Faces Securities Class Actions After April Patent Claim and Patient Death Disclosures

Fennec Q1 Sales Climb 73% to $15.1 Million on PEDMARK Momentum

ADC Therapeutics Reports Higher Q1 Sales and Lower Costs as Zenlonta Readouts Near

AstraZeneca Tops Q1 Forecasts, Reaffirms 2026 Outlook as Oncology Fuels Growth

Johnson & Johnson Tops Q1 Forecasts and Lifts 2026 Outlook

Servier to Acquire Day One Biopharma in $2.5 Billion All-Cash Deal at $21.50 a Share

Merck Lifts Mid-2030s Revenue Goal to $70 Billion From Emerging Businesses

Aktis Oncology Soars 24% in Nasdaq Debut After $318 Million IPO

AnaptysBio Seeks to Toss Tesaro Anticipatory‑Breach Claim in Jemperli Royalty Dispute

AnaptysBio and GSK’s Tesaro File Dueling Suits Over Jemperli License and Royalties

AbbVie Lifts 2025 Outlook and Dividend After Q3 Revenue Beat as Shares Fall

Merck Launches $3 Billion Cost-Optimization Program Following Q2 Revenue Miss

AstraZeneca H1 Revenue Jumps 11% as It Pledges $50 Billion U.S. Expansion